Hodgkin's disease refractory+1
Not recruitingStudy of Pembrolizumab for Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma or Primary Mediastinal Large B-cell Lymphoma
Study of Pembrolizumab for Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma or Primary Mediastinal Large B-cell Lymphoma
- Disease:Hodgkin's disease refractoryPrimary mediastinal large B-cell lymphoma refractory
- Substances:Pembrolizumab
Italy- Participants:18–64 years · 65+ years
- Substances:Pembrolizumab
- Sponsor:Merck Sharp & Dohme LLC











